An Official Website of the United States Government
CDR Grafted Antibody for Radioimmunotherapy of Lymphoma
- Small Business Information
-
Woman-Owned: NoMinority-Owned: NoHUBZone-Owned: No
- Phase 2
-
Fiscal Year: 1996Title: CDR Grafted Antibody for Radioimmunotherapy of LymphomaAgency: HHSContract: 1 R43 CA66348-01,Award Amount: $750,000.00
Abstract:
This Phase I research will test the hypothesis that an optimum, commercially viable radioimmunotherY-90-radiolabeled cdr-grafted LL2 MAb, targeted against radiosensitive Non-Hodgkin's lymphoma. Y-90because of its desirable radiophysical properties, possible use on an out-patient basis and commercicdr-grafted MAb has been selected in order to minimize human anti-mouse antibody response, which coutreatment. Conjugates will be radiolabeled using a bifunctional chelate based on 2-benzyl-DTPA, sincbe performed in 93- 98 percent incorporation yields within l hour. Y-90-labeled cdr-grafted LL2 willradiolabeled murine LL2 and to the corresponding radioiodinated antibodies for stability; in vitro cinternalization and isotope cellular retention studies, and in vivo in animal tumor xenograft modelsPhase I period, the investigators will have either confirmed the suitability of the Y-90- labeled cdradioimmunotherapy or decided that one of the other agents would be preferred, based on the combinedtumor targeting studies. The final goal is a clinically efficacious, commercially useful, radioimmunSmall Business Information at Submission:Principal Investigator:
Gary Griffiths
20105Business Contact:
Immunomedics, Inc.
300 American Road Morris Plains, NJ 07950EIN/Tax ID:DUNS: N/ANumber of Employees: N/AWoman-Owned: NoMinority-Owned: NoHUBZone-Owned: No
Award Information
|
Agency: Department of Health and Human Services |
Branch: N/A |
Award ID: 29202 |
Program Year/Program: 1996 / SBIR |
|
Agency Tracking Number: 29202 |
Solicitation Year: N/A |
Solicitation Topic Code: N/A |
Solicitation Number: N/A |